@article{article, title  = {{Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study}},

 publisher = {{Wiley}},

 url = {{}},

 year = {{2020}},

 month = {{9}},

 author = {{Cork MJ and Thaçi D and Eichenfield LF and Arkwright PD and Sun X and Chen Z and Akinlade B and Boklage S and Guillemin I and Kosloski MP and Kamal MA et al}},

 doi = {{10.1111/bjd.19460}},

 journal = {{British Journal of Dermatology}},

 note = {{Accessed on 2024/12/22}}}